Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease

Objective External fistulas represent a disabling manifestation of Crohn's disease with a difficult curability and a high relapse rate despite a large therapeutic armamentarium. Stem cell therapy is a novel and promising approach for treatment of chronic inflammatory conditions. We therefore investigated the feasibility, safety and efficacy of serial intrafistular injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in the treatment of fistulising Crohn's disease. Patients and methods We enrolled 12 consecutive outpatients (eight males, median age 32 years) refractory to or unsuitable for current available therapies. MSCs were isolated from bone marrow and expanded ex vivo to be used for both therapeutic and experimental purposes. Ten patients (two refused) received intrafistular MSC injections (median 4) scheduled every 4 weeks, and were monitored by surgical, MRI and endoscopic evaluation for 12 months afterwards. The feasibility of obtaining at least 50×106 MSCs from each patient, the appearance of adverse events, and the efficacy in terms of fistula healing and reduction of both Crohn's disease and perianal disease activity indexes were evaluated. In addition, the percentage of both mucosal and circulating regulatory T cells expressing FoxP3, and the ability of MSCs to influence mucosal T cell apoptosis were investigated. Results MSC expansion was successful in all cases; sustained complete closure (seven cases) or incomplete closure (three cases) of fistula tracks with a parallel reduction of Crohn's disease and perianal disease activity indexes (p<0.01 for both), and rectal mucosal healing were induced by treatment without any adverse effects. The percentage of mucosal and circulating regulatory T cells significantly increased during the treatment and remained stable until the end of follow up (p<0.0001 and p<0.01, respectively). Furthermore, MSCs have been proven to affect mucosal T cell apoptotic rate. Conclusions Locally injected MSCs represent a feasible, safe and beneficial therapy in refractory fistulising Crohn's disease.

[1]  G. Mancardi,et al.  Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State , 2007, Stem cells.

[2]  J. Cigudosa,et al.  Spontaneous human adult stem cell transformation. , 2005, Cancer research.

[3]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[4]  E. Lam,et al.  Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. , 2005, Blood.

[5]  A. Cometa,et al.  Inherited thrombocytopenias: from genes to therapy , 1994 .

[6]  J. Cigudosa,et al.  Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. , 2010, Experimental cell research.

[7]  R. Bjerkvig,et al.  Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. , 2010, Cancer research.

[8]  Yifan Dai,et al.  Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. , 2009, Journal of autoimmunity.

[9]  C. Shao,et al.  Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression , 2010, The Journal of Immunology.

[10]  Y. Verma,et al.  Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine , 2009, Journal of cellular and molecular medicine.

[11]  K. Ohta,et al.  Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. , 2008, Life sciences.

[12]  R. Pabst,et al.  Stromal Cells Confer Lymph Node-Specific Properties by Shaping a Unique Microenvironment Influencing Local Immune Responses1 , 2008, The Journal of Immunology.

[13]  Franco Locatelli,et al.  Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. , 2007, Blood.

[14]  S. Ng,et al.  Perianal fistulizing Crohn's disease: a call to action. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Avanzini,et al.  Phenotypical / functional characterization of in vitro expanded mesenchymal stromal cells from Crohn ’ s disease patients , 2010 .

[16]  A. Cometa,et al.  Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell‐therapy approaches: Further insights in the search for a fetal calf serum substitute , 2007, Journal of cellular physiology.

[17]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[18]  A. Cometa,et al.  Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. , 2009, Cytotherapy.

[19]  A. Cope,et al.  Cell therapy for autoimmune diseases , 2007, Arthritis research & therapy.

[20]  P. Lønning,et al.  Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. , 2009, Cancer research.

[21]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[22]  A. Cometa,et al.  Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms , 2010 .

[23]  C. Figdor,et al.  Mesenchymal stem cells respond to TNF but do not produce TNF , 2010, Journal of leukocyte biology.

[24]  D. García-Olmo,et al.  Expanded Adipose-Derived Stem Cells for the Treatment of Complex Perianal Fistula: a Phase II Clinical Trial , 2009, Diseases of the colon and rectum.

[25]  Hélène Rouard,et al.  Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.

[26]  M. Neurath,et al.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications , 2006, Gut.

[27]  Judy H. Cho,et al.  The genetics and immunopathogenesis of inflammatory bowel disease , 2008, Nature Reviews Immunology.

[28]  Mesenchymal Stromal Cells , 2013, Stem Cell Biology and Regenerative Medicine.

[29]  R. Trisolini,et al.  NOD2/CARD15 gene polymorphisms in idiopathic pulmonary fibrosis. , 2005, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[30]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[31]  M. Yacoub,et al.  Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. , 2006, Tissue engineering.

[32]  Manuel A. González,et al.  Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. , 2009, Arthritis and rheumatism.

[33]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[34]  S. Hanauer,et al.  AGA technical review on perianal Crohn's disease. , 2003, Gastroenterology.

[35]  G. Rogler,et al.  Diagnosis and management of fistulizing Crohn's disease , 2009, Nature Clinical Practice Gastroenterology &Hepatology.

[36]  S. Miller,et al.  Human bone marrow‐derived mesenchymal stem cells induce Th2‐polarized immune response and promote endogenous repair in animal models of multiple sclerosis , 2009, Glia.

[37]  G. Marchal,et al.  Magnetic Resonance Imaging of the Effects of Infliximab on Perianal Fistulizing Crohn's Disease , 2003, American Journal of Gastroenterology.

[38]  Manuel A. González,et al.  Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. , 2009, Gastroenterology.

[39]  D. García-Olmo,et al.  A Phase I Clinical Trial of the Treatment of Crohn’s Fistula by Adipose Mesenchymal Stem Cell Transplantation , 2005, Diseases of the colon and rectum.

[40]  A. Rajesh,et al.  Role of MRI in Crohn's disease. , 2009, Clinical radiology.

[41]  N. Hayashi,et al.  Topical Implantation of Mesenchymal Stem Cells Has Beneficial Effects on Healing of Experimental Colitis in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[42]  A. Levine,et al.  Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. , 1999, Journal of immunology.

[43]  W. Bloch,et al.  In vitro secreting profile of human mesenchymal stem cells. , 2008, Stem cells and development.

[44]  Judy H. Cho,et al.  [Letters to Nature] , 1975, Nature.